benzydamine has been researched along with cfm 1571 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brummell, DG; Budworth, J; Burtin, GE; Campbell, RO; Chana, SS; Charles, IG; Fernandez, PA; Glen, RC; Goggin, MC; Hobbs, AJ; Kling, MR; Liu, Q; Madge, DJ; Meillerais, S; Powell, KL; Reynolds, K; Selwood, DL; Spacey, GD; Stables, JN; Tatlock, MA; Wheeler, KA; Wishart, G; Woo, CK | 1 |
| Brummell, DG; Glen, RC; Goggin, MC; Reynolds, K; Selwood, DL; Tatlock, MA; Wishart, G | 1 |
2 other study(ies) available for benzydamine and cfm 1571
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
Topics: Animals; Enzyme Activation; Guanylate Cyclase; Humans; In Vitro Techniques; Indazoles; Male; Nitric Oxide; Platelet Aggregation Inhibitors; Pyrazoles; Rats; Rats, Sprague-Dawley; Solubility; Structure-Activity Relationship | 2001 |
Solution-Phase parallel synthesis of 5-carboxamido 1-benzyl-3-(3-dimethylaminopropyloxy)-1H-pyrazoles as activators of soluble guanylate cyclase with improved oral bioavailability.
Topics: Administration, Oral; Animals; Biological Availability; Collagen; Cyclic GMP; Enzyme Activators; Guanylate Cyclase; Inhibitory Concentration 50; Platelet Aggregation; Pyrazoles; Rats | 2001 |